Beam Therapeutics Inc. (BEAM)
| Market Cap | 2.83B |
| Revenue (ttm) | 139.74M |
| Net Income (ttm) | -79.99M |
| Shares Out | 99.31M |
| EPS (ttm) | -0.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,672,607 |
| Open | 28.78 |
| Previous Close | 28.92 |
| Day's Range | 27.57 - 28.84 |
| 52-Week Range | 13.53 - 36.44 |
| Beta | 2.13 |
| Analysts | Buy |
| Price Target | 49.13 (+72.63%) |
| Earnings Date | Feb 24, 2026 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price target is $49.13, which is an increase of 72.63% from the latest price.
News
Beam Therapeutics: Great Potential, But Patience Is Needed
Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior e...
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
What's Going On With Beam Therapeutics Stock?
Beam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectat...
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Antici...
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics: Pivoting From Platform To Execution Stage
Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a...
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application (BLA)...
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh...
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal
Beam Therapeutics Inc. remains a Strong Buy, supported by robust BEAM-101 phase 1/2 BEACON trial data in sickle cell disease. BEAM-101 consistently achieved >60% Hemoglobin F induction,
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early ...
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential
Beam Therapeutics Inc.'s base editing platform with BEAM-101 have trait-like hematology and RMAT/ODD designations. BEAM thinks this could eventually position it with a potential best-in-class SCD drug...
Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Beam Therapeutics Inc. (NASDAQ:BEAM) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 10:30 AM EDT Company Participants John Evans - CEO & Director Conference Call Participa...
Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript
Beam Therapeutics Inc. (NASDAQ:BEAM) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants John Evans - CEO & Director Conference Call Participants Samantha Se...
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from p...
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...